Enny S. Paixão

Dr. Enny S. Paixão

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Ciencia & Saude Coletiva
Verified
Journal Article
Open access
EAEstela M L Aquino
Estela M L Aquino
ISIsmael Henrique Silveira
Ismael Henrique Silveira
JPJulia Moreira Pescarini
Julia Moreira Pescarini
RARosana Aquino
Rosana Aquino
JSJaime Almeida de Souza-Filho
Jaime Almeida de Souza-Filho
RLRaíza Tourinho dos Reis Silva Lima
Raíza Tourinho dos Reis Silva Lima
Resumo A pandemia de COVID-19 tem desafiado pesquisadores e gestores a encontrar medidas de saúde pública que evitem o colapso dos sistemas de saúde e reduzam os óbitos. Esta revisão narrativa buscou sistematizar as evidências sobre o impacto das medidas de distanciamento social na epidemia de COVID-19 e discutir sua implementação no Brasil. Foram triados artigos sobre o efeito do distanciamento social na COVID-19 no PubMed, medRXiv e bioRvix, e analisados atos do poder público nos níveis federal e estadual para sumarizar as estratégias implementadas no Brasil. Os achados sugerem que o distanciamento social adotado por população é efetivo, especialmente quando combinado ao isolamento de casos e à quarentena dos contatos. Recomenda-se a implementação de medidas de distanciamento social e de políticas de proteção social para garantir a sustentabilidade dessas medidas. Para o controle da COVID-19 no Brasil, é imprescindível que essas medidas estejam aliadas ao fortalecimento do sistema de vigilância nos três níveis do SUS, que inclui a avaliação e uso de indicadores adicionais para monitorar a evolução da pandemia e o efeito das medidas de controle, a ampliação da capacidade de testagem, e divulgação ampla e transparente das notificações e de testagem desagregadas.

1 April 2016 in American Journal of Public Health
Verified
Journal Article
Closed access
EPEnny S. Paixão
Enny S. Paixão
FBFlorisneide Barreto
Florisneide Barreto
MTMaria da Glória Teixeira
Maria da Glória Teixeira
MCMaria da Conceição N. Costa
Maria da Conceição N. Costa
LRLaura C. Rodrigues
Laura C. Rodrigues
Objectives. To describe salient epidemiological characteristics of Zika virus outbreaks across the world and to examine the clinical presentations, complications, and atypical manifestations related to their occurrence in recent history. Methods. We conducted a systematic review of the literature by searching through MEDLINE, Embase, and Global Health Library, as well as the epidemiological bulletins and alerts from the World Health Organization, the Pan American Health Organization, and the European Centre for Disease Prevention and Control over the period 1954 to 2016. Results. The search yielded 547 records. We retained 333 for further analysis, to which we added 11 epidemiological bulletins from various sources. Of these, we systematically reviewed 52 articles and reports, revealing some epidemiological features and patterns of spread of the Zika virus worldwide, as well as pathological outcomes suspected to be linked to Zika outbreaks. Neurologic disorders among zika patients were similar in Brazil and French Polynesia but a causal link is not established. Incidence of zika infection in pregnant women is not known. In Brazil, during the zika outbreak the incidence of microcephaly increased more than 20 times. Among 35 infants with microcephaly, born from women suspected to have Zika infection during pregnancy in northeast Brazil, 74% of the mothers reported rash during the first and second trimester. Conclusions. On February 1, 2016, The World Health Organization declared the ongoing Zika crisis an emergency and that, although not yet scientifically proven, the link between the virus and growing numbers of microcephaly cases was “strongly suspected.” However, the causal relationship between zika and microcephaly is not universally accepted. Public Health Implications. The current situation with regard to Zika is not encouraging, because there is no vaccine, no treatment, and no good serological test, and vector control remains a challenge.

1 July 2016 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
EPEnny S. Paixão
Enny S. Paixão
MTMaria Gloria Teixeira
Maria Gloria Teixeira
MCMaria da Conceição N Costa
Maria da Conceição N Costa
LRLaura C Rodrigues
Laura C Rodrigues

9 February 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
TCThiago Cerqueira-Silva Cerqueira-Silva
Thiago Cerqueira-Silva Cerqueira-Silva
SKSrinivasa Vittal Katikireddi
Srinivasa Vittal Katikireddi
VOVinicius de Araujo Oliveira
Vinicius de Araujo Oliveira
RFRenzo Flores-Ortiz
Renzo Flores-Ortiz
JJJuracy Bertoldo Júnior
Juracy Bertoldo Júnior
VBViviane Sampaio Boaventura
Viviane Sampaio Boaventura
There is considerable interest in the waning of effectiveness of coronavirus disease 2019 (COVID-19) vaccines and vaccine effectiveness (VE) of booster doses. Using linked national Brazilian databases, we undertook a test-negative design study involving almost 14 million people (~16 million tests) to estimate VE of CoronaVac over time and VE of BNT162b2 booster vaccination against RT–PCR-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe COVID-19 outcomes (hospitalization or death). Compared with unvaccinated individuals, CoronaVac VE at 14–30 d after the second dose was 55.0% (95% confidence interval (CI): 54.3–55.7) against confirmed infection and 82.1% (95% CI: 81.4–82.8) against severe outcomes. VE decreased to 34.7% (95% CI: 33.1–36.2) against infection and 72.5% (95% CI: 70.9–74.0) against severe outcomes over 180 d after the second dose. A BNT162b2 booster, 6 months after the second dose of CoronaVac, improved VE against infection to 92.7% (95% CI: 91.0−94.0) and VE against severe outcomes to 97.3% (95% CI: 96.1−98.1) 14–30 d after the booster. Compared with younger age groups, individuals 80 years of age or older had lower protection after the second dose but similar protection after the booster. Our findings support a BNT162b2 booster vaccine dose after two doses of CoronaVac, particularly for the elderly.

18 December 2021 in International Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
MBMauricio L Barreto
Mauricio L Barreto
MIMaria Yury Ichihara
Maria Yury Ichihara
JPJulia M Pescarini
Julia M Pescarini
MAM Sanni Ali
M Sanni Ali
GBGabriela L Borges
Gabriela L Borges
LSLiam Smeeth
Liam Smeeth
Key FeaturesThe creation of The 100 Million Brazilian Cohort was motivated by the availability of high quality but dispersed social and health databases in Braz

28 September 2021 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
Dandara de Oliveira RamosDandara de Oliveira Ramos
Dandara de Oliveira Ramos
NSNívea B. da Silva
Nívea B. da Silva
MIMaria Yury Travassos Ichihara
Maria Yury Travassos Ichihara
RFRosemeire L. Fiaccone
Rosemeire L. Fiaccone
DADaniela Almeida
Daniela Almeida
MBMaurício L. Barreto
Maurício L. Barreto
Background: Brazil has made great progress in reducing child mortality over the past decades, and a parcel of this achievement has been credited to the Bolsa Família program (BFP). We examined the association between being a BFP beneficiary and child mortality (1–4 years of age), also examining how this association differs by maternal race/skin color, gestational age at birth (term versus preterm), municipality income level, and index of quality of BFP management. Methods and findings: This is a cross-sectional analysis nested within the 100 Million Brazilian Cohort, a population-based cohort primarily built from Brazil’s Unified Registry for Social Programs (Cadastro Único). We analyzed data from 6,309,366 children under 5 years of age whose families enrolled between 2006 and 2015. Through deterministic linkage with the BFP payroll datasets, and similarity linkage with the Brazilian Mortality Information System, 4,858,253 children were identified as beneficiaries (77%) and 1,451,113 (23%) were not. Our analysis consisted of a combination of kernel matching and weighted logistic regressions. After kernel matching, 5,308,989 (84.1%) children were included in the final weighted logistic analysis, with 4,107,920 (77.4%) of those being beneficiaries and 1,201,069 (22.6%) not, with a total of 14,897 linked deaths. Overall, BFP participation was associated with a reduction in child mortality (weighted odds ratio [OR] = 0.83; 95% CI: 0.79 to 0.88; p < 0.001). This association was stronger for preterm children (weighted OR = 0.78; 95% CI: 0.68 to 0.90; p < 0.001), children of Black mothers (weighted OR = 0.74; 95% CI: 0.57 to 0.97; p < 0.001), children living in municipalities in the lowest income quintile (first quintile of municipal income: weighted OR = 0.72; 95% CI: 0.62 to 0.82; p < 0.001), and municipalities with better index of BFP management (5th quintile of the Decentralized Management Index: weighted OR = 0.76; 95% CI: 0.66 to 0.88; p < 0.001). The main limitation of our methodology is that our propensity score approach does not account for possible unmeasured confounders. Furthermore, sensitivity analysis showed that loss of nameless death records before linkage may have resulted in overestimation of the associations between BFP participation and mortality, with loss of statistical significance in municipalities with greater losses of data and change in the direction of the association in municipalities with no losses. Conclusions: In this study, we observed a significant association between BFP participation and child mortality in children aged 1–4 years and found that this association was stronger for children living in municipalities in the lowest quintile of wealth, in municipalities with better index of program management, and also in preterm children and children of Black mothers. These findings reinforce the evidence that programs like BFP, already proven effective in poverty reduction, have a great potential to improve child health and survival. Subgroup analysis revealed heterogeneous results, useful for policy improvement and better targeting of BFP.